Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. (Vor Bio) (Nasdaq: VOR) is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through the development of telitacicept, a dual BAFF/APRIL fusion protein. The VOR news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Vor Bio’s telitacicept program and corporate strategy evolve over time.
According to recent announcements, Vor Bio’s news flow centers on late-stage clinical data for telitacicept in B‑cell–mediated autoimmune diseases, including generalized myasthenia gravis, Sjögren’s disease, systemic lupus erythematosus, and IgA nephropathy. The company and its collaborator RemeGen Co., Ltd. have reported Phase 3 results from studies conducted in China, including data presented at major medical meetings and in peer‑reviewed publications. These updates highlight efficacy endpoints, durability of response, and safety findings for telitacicept across multiple indications.
Investors following VOR news can also track capital markets activity, such as underwritten public offerings, private placements with institutional healthcare investors, and at‑the‑market equity sales programs disclosed in company press releases and Form 8‑K filings. Additional news items cover leadership and governance changes, including appointments to the Board of Directors and executive team roles like Chief Medical Officer, Chief Development Officer, and Chief Commercial Officer, which Vor Bio links to its late-stage development and potential commercialization plans.
Vor Bio’s participation in healthcare and investor conferences, including events such as the J.P. Morgan Healthcare Conference and other sector-focused meetings, is another recurring news theme. Visitors to this page can review updates on upcoming presentations, webcasts, and corporate slide decks referenced in SEC filings. For anyone monitoring VOR, the news feed offers a centralized view of clinical milestones, financing decisions, and strategic developments related to telitacicept and Vor Bio’s broader autoimmune disease focus.
Vor Bio (Nasdaq: VOR) will present and hold 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston.
The company presentation is scheduled for Monday, March 2, 2026, 9:50–10:20 AM ET. A live webcast and archived replay will be available for 90 days on the company website.
Vor Bio (Nasdaq: VOR) will present and host one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Tuesday, January 13, 2026, 10:30 AM–11:10 AM PT at The Westin St. Francis, Georgian Room. A live webcast and archived replay will be available on the company website at https://ir.vorbio.com/events-presentations/. The company is clinical-stage and focuses on autoimmune disease treatments.
Vor Biopharma (Nasdaq: VOR) announced the appointment of Andrew Levin, M.D., Ph.D. of RA Capital and Wouter Joustra of Forbion to its Board of Directors on December 23, 2025.
The appointments follow a $150M PIPE financing that included participation from both investors. Vor Bio said the new directors will support advancement of telitacicept through global Phase 3 programs and contribute to financing and governance strategy. Dr. Levin replaces Sarah Reed, who resigned from the Board. Both appointees are described as having deep life‑sciences investment and late‑stage biotech experience.
Vor Bio (Nasdaq: VOR) entered a securities purchase agreement to sell 13,876,032 shares of common stock at $10.81 per share, expecting gross proceeds of approximately $150 million before expenses. The private placement is expected to close on or about December 18, 2025, subject to customary conditions, and no placement agent was engaged.
Investors include RA Capital, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, and Venrock Healthcare Capital Partners; Forbion receives the right to appoint one director. Vor Bio plans to use net proceeds to advance development of telitacicept, including a global Phase 3 trial for myasthenia gravis and initiation of a global Phase 3 trial in primary Sjögren's disease, plus working capital. Registration rights will be filed with the SEC for resale of the placement shares.
Vor Bio (NASDAQ: VOR) reported Q3 2025 results and a broad clinical and corporate update on November 13, 2025. Multiple Phase 3 readouts for telitacicept showed positive efficacy and favorable safety across indications: gMG (96.2% ≥3‑point MG‑ADL response at 48 weeks), Sjögren’s disease (placebo‑adjusted ESSDAI −3.8; 71.8% vs 19.3% ≥3‑point ESSDAI at 24 weeks), SLE (67.1% vs 32.7% modified SRI‑4 at Week 52), and IgA nephropathy (55% reduction in 24h‑UPCR at 39 weeks). Corporate: raised expected gross proceeds of $115 million in Nov 2025 offering; cash and marketable securities were $170.5M as of Sept 30, 2025, projected to fund operations into Q2 2027.
Q3 financials show a net loss of $812.7M driven by a loss on warrant liabilities and total liabilities of $2.402B.
Vor Bio (Nasdaq: VOR) priced an underwritten public offering of 10,000,000 common shares at $10.00 per share, generating expected gross proceeds of $100 million before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about November 12, 2025. Vor Bio granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price, less underwriting discounts and commissions. All shares are being sold by Vor Bio pursuant to a shelf registration declared effective by the SEC on March 31, 2025. Final prospectus supplement will be filed with the SEC and copies will be available from the listed underwriters.
Vor Bio (Nasdaq: VOR) commenced an underwritten public offering of $100 million of common stock on November 10, 2025, and intends to grant underwriters a 30-day option to purchase up to an additional $15 million of shares at the public offering price, less underwriting discounts and commissions.
All shares are being offered by Vor Bio and the offering is subject to market and other conditions with no assurance it will be completed as proposed. J.P. Morgan, Jefferies, Citigroup and TD Cowen are joint book-running managers. The offering uses a shelf registration declared effective March 31, 2025, and will be made by prospectus supplement filed with the SEC.
Vor Bio (Nasdaq: VOR) reported that telitacicept met the primary endpoint in Stage A of a Phase 3 IgA nephropathy study in China, showing a rapid, clinically meaningful proteinuria reduction at Week 39.
Key metrics: 24h-UPCR -58.9% vs -8.8% (p<0.0001); eGFR stabilized (telitacicept -0.10 vs placebo -0.77); risk of ≥30% eGFR decline 6.3% vs 27.0%; remission rates 61% vs 19.5% for UPCR <0.8 g/g. Safety: more treatment-emergent AEs with telitacicept (89.3% vs 78.6%) but fewer serious AEs (2.5% vs 8.2%). RemeGen submitted a BLA to China regulators for IgAN.
Vor Bio (Nasdaq: VOR) will participate in two upcoming investor conferences in November–December 2025. The company will host a fireside chat at the TD Cowen Virtual Immunology & Inflammation Summit on Wednesday, November 12, 2025 at 2:30 PM ET, and a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 3:00 PM ET in Miami, FL.
A live webcast and archived replay of both fireside chats will be available on the investors section of www.vorbio.com.
Vor Bio (Nasdaq: VOR) announced the appointment of Jeremy Sokolove, M.D. as Chief Medical Officer effective Nov 3, 2025. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development.
His recent roles include Chief Medical Officer In-Residence at Roivant Sciences, Chief Medical Officer at Odyssey Therapeutics, Senior VP and Head of Clinical Pharmacology at GSK, and Head of Immunology Translational Science at AbbVie. He began his career on the faculty at Stanford and holds an MD from Boston University School of Medicine.
The company says Dr. Sokolove will drive clinical strategy and lead the global development program for Telitacicept, targeting BAFF/APRIL pathways to address autoimmune diseases.